AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Generics Market Outlook, 2019-2030: Focus on Value-Added Medicines/Supergenerics - ResearchAndMarkets.com

November 4, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Nov 4, 2019--

The “Generics Market: Focus on Value-Added Medicines / Supergenerics, 2019-2030” report has been added to ResearchAndMarkets.com’s offering.

This report features an extensive study of supergenerics, as well as the current landscape and future potential of technology providers that are offering innovative platforms / solutions to supergeneric drug developers.

In 2018, it was estimated that the availability of low-cost, generic versions of pharmaceutical interventions saved nearly USD 1.6 trillion in healthcare costs in the US over the last decade. Given the cost benefits offered, generic medicines usually have high adoption rates. Moreover, upcoming patent expiries of several blockbuster drugs, such as LYRICA, Cialis, Advair and Sensipar, have intensified the interest of several drug manufacturers in the development of generics.

As more generic drugs get approved by regulators across the globe, the competition in the industry has steadily increased. Interestingly, in 2018, the US FDA approved more than 780 generic products, which represented more than 90% increase in the number of such drug approvals since 2014.

The most evident impact of the growth in competition in this domain is deflation of cost of generics, resulting in diminished profit margins for the developers of such products. Therefore, to ensure sustainable growth within the off-patent drug products market, companies are gradually adopting innovative drug alteration techniques in order to develop value-added medicinal products, which offer better commercial benefits.

The availability of several advanced drug development and technology platforms have enabled the fabrication and formulation of improved versions of existing drug products. Such modified pharmacological interventions are commonly referred to as supergenerics / complex generics / value-added generics.

Although supergenerics are based on the same mechanism of action as that of the original drug, these versions usually have certain additional attributes, such as a new active ingredient, improved manufacturing process, alternative dosage regimen, modified release properties or different formulation. Typically, such drugs are granted a form of marketing exclusivity (for a period of 3-7 years), enabling their developers to generate relatively higher profit margins, compared to conventional generics.

Moreover, the development of value-added generics is generally directed at certain unmet clinical needs, which may have been unaddressed by previous versions of the drug. In addition, the approval process for such products is not as complicated; in the US, value-added medicines are evaluated under the FDA’s 505(b)(2) pathway.

This evolving segment of the pharmaceutical industry has also witnessed a surge in the availability of technology providers, offering a diverse range of platforms / solutions to support the development of supergeneric drugs. After a detailed analysis of prevalent trends, we are led to believe that value-added generic products market is poised to witness significant growth over the coming years.

Report Scope

One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity within the market. Based on several parameters, such as size of the generic drugs market, share of supergenerics within the generic drugs market and expected annual growth rate across various geographies, we have provided an informed estimate of the likely evolution of the market, in the mid to long term, for the period 2019-2030.

The chapter also presents a detailed market segmentation across [A] different therapeutic areas (autoimmune disorders, cardiovascular disorders, CNS disorders, metabolic disorders, oncological disorders, pain disorders, respiratory disorders and others), [B] routes of administration (parenteral, intravitreal, oral, topical and others) and [C] key geographical regions (North America, Asia-Pacific, Europe, South America, and Africa and Middle East).

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Key Topics Covered

1 Preface

2 Executive Summary

3 Introduction

4 Supergeneric Drugs: Market Landscape

5 Technology Providers for Supergeneric Development: Market Landscape

6 Company Profiles: Supergeneric Technology Providers

7 Case Study of Approved Supergeneric Drugs

8 Likely Drug Candidates for Supergeneric Development

9 SWOT Analysis

10 Market Forecast

11 Conclusion

12 Appendix 1: Tabulated Data

13 Appendix 2: List of Companies & Organization

For more information about this report visit https://www.researchandmarkets.com/r/2e6j7u

View source version on businesswire.com:https://www.businesswire.com/news/home/20191104005401/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/04/2019 06:43 AM/DISC: 11/04/2019 06:43 AM

http://www.businesswire.com/news/home/20191104005401/en